X4 PHARMACEUTICALS, INC.
61 North Beacon Street, 4th Floor
Boston, MA 02134
December 30, 2021
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Jordan Nimitz |
| RE: | X4 Pharmaceuticals, Inc. |
| Registration Statement on Form S-3 |
| File No. 333-261871 |
| Acceleration Request |
| Requested Date: | January 3, 2022 | |
| Requested Time: | 4:00 p.m. Eastern Time |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-261871) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on Monday, January 3, 2022, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Daniel I. Goldberg of Cooley LLP, counsel to the registrant, at (212) 479-6722.
[Signature page follows]
| Sincerely, | ||
| X4 PHARMACEUTICALS, INC. | ||
| By: | /s/ Adam S. Mostafa | |
| Adam S. Mostafa | ||
| Chief Financial Officer | ||
| cc: | Paula Ragan, Ph.D., Chief Executive Officer, X4 Pharmaceuticals, Inc. |
| Derek Meisner, Chief Legal Officer, X4 Pharmaceuticals, Inc. |
| Daniel I. Goldberg, Cooley LLP |
| Courtney T. Thorne, Cooley LLP |